Pfizer Expects Favorable Labeling For Oncologic Sutent
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for sunitinib “might surprise us all,” CEO McKinnell tells investors.
You may also be interested in...
Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer
Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.
Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer
Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.
Bayer/Onyx’ Nexavar Approved For Kidney Cancer
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.